Cosentyx vs Rinvoq
Side-by-side cost comparison based on Medicare Part D data
Cosentyx
Secukinumab
Manufactured by Novartis
Rinvoq
Upadacitinib
Manufactured by AbbVie
Rinvoq costs 3% less per claim than Cosentyx ($3,498.00 vs $3,616.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Cosentyx | Rinvoq |
|---|---|---|
| Avg Cost Per Claim | $3,616.00 | $3,498.00 |
| Total Medicare Spending | $3.1B | $2.3B |
| Total Beneficiaries | 120,000 | 92,000 |
| Total Claims | 864,000 | 648,000 |
| Annual Cost/Patient | $26,033.00 | $24,641.00 |
| Year-over-Year Change | +8.9% | +56.3% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Aug 16, 2033 |
| Manufacturer | Novartis | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Secukinumab | Upadacitinib |
Cosentyx vs Rinvoq: What the Data Shows
Cosentyx (Secukinumab) and Rinvoq (Upadacitinib) are both used to treat autoimmune diseases. Based on Medicare Part D data, Rinvoq costs $3,498.00 per claim, which is 3% less than Cosentyx at $3,616.00 per claim.
Medicare spent $3.1B on Cosentyx and $2.3B on Rinvoq. In terms of patient reach, Cosentyx serves more beneficiaries (120,000 vs 92,000).
Year-over-year spending changed +8.9% for Cosentyx and +56.3% for Rinvoq. Rinvoq saw significant spending growth, suggesting increased utilization or price increases.
Cosentyx has a generic available, while Rinvoq remains brand-only until its patent expires Aug 16, 2033.
Frequently Asked Questions
Rinvoq is cheaper at $3,498.00 per claim, compared to $3,616.00 for Cosentyx. That makes Rinvoq about 3% less expensive per claim based on Medicare Part D data.
Yes, both Cosentyx and Rinvoq are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Cosentyx has a generic version (Secukinumab) available, which is typically much cheaper. Rinvoq is currently brand-only, with patent expiring Aug 16, 2033.
Medicare Part D spent $3.1B on Cosentyx covering 120,000 beneficiaries, and $2.3B on Rinvoq covering 92,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.